Andes Biotechnologies Overview

  • Founded
  • 2008
  • Status
  • Out of Business
  • Employees
  • 3
  • Latest Deal Type
  • Out of Business

Andes Biotechnologies General Information


Developer of novel therapeutics intended to create a new class of drugs for the treatment of cancer. The company's therapeutics use antisense technologies to target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis, thereby enabling physicians to selectively destroy cancer cells without affecting normal cells.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Parque Tecnológico Zañartu
  • Av. Zañartu, Ñuñoa
  • Santiago, 1482
  • Chile
+56 000000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Andes Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 20-Dec-2020 0000 Completed Out of Business
6. Later Stage VC 01-Jun-2018 0000 0000 Completed Generating Revenue
5. Later Stage VC (Series B) 15-Apr-2015 0000 0000 Completed Generating Revenue
4. Later Stage VC 10-Mar-2014 000 000 Completed Generating Revenue
3. Early Stage VC 10-May-2012 000 000 Completed Generating Revenue
2. Early Stage VC (Series A) 19-May-2011 $4M $4M Completed Generating Revenue
1. Grant 11-Jan-2011 Completed Startup
To view Andes Biotechnologies’s complete valuation and funding history, request access »

Andes Biotechnologies Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial